Every Form 4 that Natera Inc (NTRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NTRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRA filings page.
Natera (NTRA) reported an insider equity change by its SEC. and Chief Legal Officer. On 10/20/2025, 856 shares of common stock were acquired through the vesting of RSUs, and on 10/21/2025, 464 shares were sold at $187.95 to cover tax withholding and remittance obligations pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following these transactions, the officer directly owned 203,692 shares. Each RSU represents a right to receive one share. The RSUs vest over four years: 25% vested on January 20, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction on a Form 4. An officer serving as President, Clinical Diagnostics sold 292 shares of common stock at $187.95 on 10/21/2025. The filing states the sale was made to satisfy tax withholding obligations related to RSU vesting and was conducted under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Following the transaction, the officer beneficially owned 117,267 shares, held directly.
Natera, Inc. (NTRA) disclosed a Form 4 for its President and Chief Business Officer reporting a sale of 339 shares of common stock on 10/21/2025 at $187.95 per share (code S). The filing states the shares were sold to satisfy tax withholding and remittance obligations tied to vesting RSUs and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the transaction, the officer directly owned 152,408 shares.
Natera (NTRA) reported an insider transaction by its CEO and President, who is also a director. On 10/20/2025, 3,386 Restricted Stock Units vested and were converted to common stock (code M). On 10/21/2025, 1,603 shares were sold at $187.95 per share (code S) to satisfy tax withholding, under a Rule 10b5-1(c) instruction tied to a January 28, 2022 grant. Following these transactions, the reporting person directly beneficially owns 155,855 shares.
The RSU award vests over four years: 25% on January 20, 2023, with the remainder in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction by its chief financial officer. On Oct 20, 2025, 1,522 RSUs vested and were settled into common stock. On Oct 21, 2025, 602 shares were sold at $187.95 to satisfy tax withholding, pursuant to a written instruction intended to meet Rule 10b5-1(c) conditions. Following these transactions, the officer held 70,109 shares directly.
The RSUs relate to a grant dated Jan 28, 2022 and vest over four years: 25% vested on Jan 20, 2023, with the balance vesting in 12 equal quarterly installments thereafter.
Natera (NTRA) co‑founder and director reported open‑market sales of common stock made under Rule 10b5‑1 trading plans. On 10/15/2025, sales of 153, 1,506, 988, and 423 shares executed at weighted average prices of $172.9918, $175.1097, $175.8967, and $176.6252. Direct holdings were 236,112 shares after these transactions.
On 10/17/2025, trusts sold 475, 275, 413, and 337 shares at weighted average prices of $178.6601, $179.3511, $178.5818, and $179.2912. Indirect holdings were 28,032 shares in Caraluna 1 Trust and 28,032 shares in Caraluna 2 Trust; the reporting person disclaims beneficial ownership of trust-held shares.
Insider filing summary: Natera, Inc. director and Secretary & Chief Legal Officer Daniel Rabinowitz had 2,500 restricted stock units (RSUs) vest on 09/29/2025, each representing one share. Those RSUs converted into 2,500 shares of common stock. On 09/30/2025 the reporting person sold 1,364 shares at $162.0528 per share to satisfy tax withholding obligations tied to the RSU vesting, leaving the reporting person with 203,300 shares beneficially owned after the transactions. The sale was made pursuant to written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.
Michael Brophy, Chief Financial Officer of Natera, Inc. (NTRA), reported vesting and a subsequent sale of shares tied to restricted stock units. On 09/29/2025 6,250 RSUs vested from a 25,000-share grant originally issued on 01/22/2021, where each RSU converts to one share. The reporting shows an immediate beneficial ownership increase to 71,680 shares, followed by a sale on 09/30/2025 of 2,491 shares at $162.0528 per share to satisfy tax withholding, leaving 69,189 shares beneficially owned. The sale was carried out under a written instruction intended to meet Rule 10b5-1(c) conditions. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Insider sales by a Natera director under pre-established plans — Sheena Jonathan, a director and co-founder of Natera, reported multiple sales of NTRA common stock executed under Rule 10b5-1 trading plans. On 09/17/2025 she sold 2,814 shares at a weighted average of $175.8835 and 256 shares at $176.6094, leaving 239,182 shares directly owned. On 09/19/2025 additional sales were reported including 3,444 shares and several smaller lots sold on behalf of two trusts, with reported weighted average prices in the $178.51 to $180.69 ranges. The filings state the trust-held shares are disclaimed as beneficial ownership by the reporting person.
Natera, Inc. (NTRA) insider Matthew Rabinowitz reported sales totaling 50,000 shares of common stock on September 18-19, 2025. The dispositions were effected under two separate Rule 10b5-1 trading plans adopted on June 13, 2025 and March 14, 2025, with reported weighted-average prices in ranges around $180.00–$181.40 per share. After these transactions the reporting person directly beneficially owned 2,320,852 shares and indirectly beneficially owned 15,000 shares through a spouse. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on September 19, 2025.
Natera insider reported a minor disposition of common stock via charitable contribution. Solomon Moshkevich, listed as President, Clinical Diagnostics and an officer of Natera, executed a gift of 300 shares of Natera common stock on 09/15/2025, recorded as a disposition at $0 per share. After the reported transaction he beneficially owns 120,559 shares directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025 and notes the sale was a charitable contribution.
Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NTRA), reported sales of common stock under a pre-established trading plan. On 09/12/2025 the filing shows a total of 5,000 shares sold (4,500 and 500 shares) at prices reported as a weighted average of $170.3083 for one block and $172.64 for the other, with the larger block sold at prices ranging from $170.00 to $170.93. The Form states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
The filing lists 2,360,852 shares beneficially owned directly following the reported transactions. It also records indirect holdings attributed to a spouse of 25,500 and 25,000 shares on separate lines. The Form 4 was signed by an attorney-in-fact on 09/16/2025.